Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America

Abstract Background CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year foll...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2021-09, Vol.73 (6), p.1003-1012
Main Authors: Forrat, Rémi, Dayan, Gustavo H, DiazGranados, Carlos A, Bonaparte, Matthew, Laot, Thelma, Capeding, Maria Rosario, Sanchez, Leilani, Coronel, Diana Leticia, Reynales, Humberto, Chansinghakul, Danaya, Hadinegoro, Sri Rezeki S, Perroud, Ana Paula, Frago, Carina, Zambrano, Betzana, Machabert, Tifany, Wu, Yukun, Luedtke, Alexander, Price, Brenda, Vigne, Claire, Haney, Owen, Savarino, Stephen J, Bouckenooghe, Alain, Noriega, Fernando
Format: Article
Language:English
Subjects:
Major and Commentaries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). Methods The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciab288